TargTex is determined to find novel correlations between small molecules and targets that are overexpressed in oncological indication. Our lead product is being developed as an adjunct to surgery taking advantage its selectivity towards an unexplored target in Glioblastoma Multiforme.
Our Mission
TargTex is developing a concerted approach, aligning scientists, physicians and patients to advance an innovative therapy to treat a daunting disease, giving a chance to Glioblastoma Multiforme patients to live instead of surviving.
Latest News
News / Events / Awards / Publications
The U.S. Food and Drug Administration (FDA) granted orphan-drug designation (ODD) to TTX101 for use in patients with malignant gliomas.
...
AI and Quantitative image analysis will help to identify early treatment changes in GBM patients and support the development of predictive response markers....
The start-up TargTex and the pharmaceutical company Basi close a seed-extension investment
...
These awards are attributed by Exame Informática ...
Researchers form the Instituto de Medicina Molecular have created an artificial intelligence platform ...
0